Laboratorio Reig Jofre, S.A. Logo

Laboratorio Reig Jofre, S.A.

RJF.MC

(3.2)
Stock Price

2,90 EUR

3.44% ROA

4.5% ROE

24.19x PER

Market Cap.

224.167.362,00 EUR

27.64% DER

1.16% Yield

2.79% NPM

Laboratorio Reig Jofre, S.A. Stock Analysis

Laboratorio Reig Jofre, S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Laboratorio Reig Jofre, S.A. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.98x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (36%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

6 ROE

ROE in an average range (2.73%) suggests satisfactory profitability and decent utilization of shareholders' equity.

7 ROA

The stock's ROA (2.34%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

8 Buffet Intrinsic Value

The company's stock seems undervalued (70) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

9 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Laboratorio Reig Jofre, S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Laboratorio Reig Jofre, S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Laboratorio Reig Jofre, S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Laboratorio Reig Jofre, S.A. Revenue
Year Revenue Growth
2004 23.219.101
2005 46.981.000 50.58%
2006 90.762.000 48.24%
2007 152.916.000 40.65%
2008 161.019.000 5.03%
2009 134.616.000 -19.61%
2010 38.841.000 -246.58%
2011 29.485.000 -31.73%
2012 29.926.000 1.47%
2013 31.370.000 4.6%
2014 33.284.362 5.75%
2015 156.909.656 78.79%
2016 161.134.290 2.62%
2017 167.983.166 4.08%
2018 180.467.786 6.92%
2019 200.207.000 9.86%
2020 230.079.000 12.98%
2021 236.231.000 2.6%
2022 271.150.000 12.88%
2023 320.364.000 15.36%
2023 316.088.000 -1.35%
2024 345.232.000 8.44%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Laboratorio Reig Jofre, S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 67.000 100%
2013 100.000 33%
2014 627.182 84.06%
2015 2.503.612 74.95%
2016 3.298.290 24.09%
2017 3.692.229 10.67%
2018 4.097.249 9.89%
2019 4.017.000 -2%
2020 3.797.000 -5.79%
2021 4.885.000 22.27%
2022 4.478.000 -9.09%
2023 0 0%
2023 5.428.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Laboratorio Reig Jofre, S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 0
2005 0 0%
2006 347.000 100%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 3.544.000 100%
2013 3.071.000 -15.4%
2014 994.324 -208.85%
2015 8.538.862 88.36%
2016 10.310.267 17.18%
2017 8.829.093 -16.78%
2018 5.410.868 -63.17%
2019 10.159.000 46.74%
2020 8.427.000 -20.55%
2021 9.234.000 8.74%
2022 9.002.000 -2.58%
2023 0 0%
2023 9.724.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Laboratorio Reig Jofre, S.A. EBITDA
Year EBITDA Growth
2004 5.577.271
2005 5.141.000 -8.49%
2006 11.672.000 55.95%
2007 2.876.000 -305.84%
2008 20.255.000 85.8%
2009 -28.940.000 169.99%
2010 -262.000 -10945.8%
2011 1.360.000 119.26%
2012 1.022.000 -33.07%
2013 2.549.000 59.91%
2014 3.623.148 29.65%
2015 17.163.229 78.89%
2016 14.924.064 -15%
2017 15.450.609 3.41%
2018 16.391.020 5.74%
2019 19.364.000 15.35%
2020 26.719.000 27.53%
2021 26.958.000 0.89%
2022 30.436.000 11.43%
2023 30.536.000 0.33%
2023 35.136.000 13.09%
2024 39.232.000 10.44%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Laboratorio Reig Jofre, S.A. Gross Profit
Year Gross Profit Growth
2004 7.547.479
2005 20.863.000 63.82%
2006 44.138.000 52.73%
2007 85.633.000 48.46%
2008 99.628.000 14.05%
2009 68.094.000 -46.31%
2010 29.223.000 -133.02%
2011 21.654.000 -34.95%
2012 21.971.000 1.44%
2013 23.228.000 5.41%
2014 19.871.920 -16.89%
2015 97.775.968 79.68%
2016 100.110.805 2.33%
2017 107.646.833 7%
2018 117.672.640 8.52%
2019 131.921.000 10.8%
2020 140.397.000 6.04%
2021 144.979.000 3.16%
2022 69.583.000 -108.35%
2023 176.804.000 60.64%
2023 85.174.000 -107.58%
2024 87.920.000 3.12%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Laboratorio Reig Jofre, S.A. Net Profit
Year Net Profit Growth
2004 3.057.064
2005 3.757.000 18.63%
2006 4.549.000 17.41%
2007 3.841.000 -18.43%
2008 1.491.000 -157.61%
2009 -44.907.000 103.32%
2010 -22.618.000 -98.55%
2011 16.066.000 240.78%
2012 -6.000 267866.67%
2013 953.000 100.63%
2014 2.308.394 58.72%
2015 8.749.701 73.62%
2016 7.676.288 -13.98%
2017 8.828.435 13.05%
2018 9.266.277 4.73%
2019 4.942.000 -87.5%
2020 5.672.000 12.87%
2021 5.092.000 -11.39%
2022 8.107.000 37.19%
2023 8.764.000 7.5%
2023 9.407.000 6.84%
2024 9.104.000 -3.33%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Laboratorio Reig Jofre, S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 0
2005 0 0%
2006 0 0%
2007 1 0%
2008 0 0%
2009 -3 100%
2010 -1 -100%
2011 1 200%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Laboratorio Reig Jofre, S.A. Free Cashflow
Year Free Cashflow Growth
2005 -39.050.000
2006 -1.644.000 -2275.3%
2007 19.873.000 108.27%
2008 9.595.000 -107.12%
2009 -29.604.000 132.41%
2010 -6.012.000 -392.42%
2011 -7.751.000 22.44%
2012 -6.378.000 -21.53%
2013 -86.000 -7316.28%
2014 -10.787.226 99.2%
2015 2.395.905 550.24%
2016 -13.733.510 117.45%
2017 3.129.427 538.85%
2018 -6.311.638 149.58%
2019 -19.466.000 67.58%
2020 6.554.000 397.01%
2021 -5.265.000 224.48%
2022 4.747.999 210.89%
2023 11.354.000 58.18%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Laboratorio Reig Jofre, S.A. Operating Cashflow
Year Operating Cashflow Growth
2005 -10.308.000
2006 6.837.000 250.77%
2007 31.568.000 78.34%
2008 17.889.000 -76.47%
2009 -23.460.000 176.25%
2010 -5.024.000 -366.96%
2011 -7.110.000 29.34%
2012 -5.892.000 -20.67%
2013 396.000 1587.88%
2014 -3.305.537 111.98%
2015 12.871.578 125.68%
2016 -1.489.763 964%
2017 20.693.072 107.2%
2018 14.765.914 -40.14%
2019 11.679.000 -26.43%
2020 22.504.000 48.1%
2021 14.497.000 -55.23%
2022 16.146.999 10.22%
2023 11.354.000 -42.21%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Laboratorio Reig Jofre, S.A. Capital Expenditure
Year Capital Expenditure Growth
2005 28.742.000
2006 8.481.000 -238.9%
2007 11.695.000 27.48%
2008 8.294.000 -41.01%
2009 6.144.000 -34.99%
2010 988.000 -521.86%
2011 641.000 -54.13%
2012 486.000 -31.89%
2013 482.000 -0.83%
2014 7.481.689 93.56%
2015 10.475.673 28.58%
2016 12.243.747 14.44%
2017 17.563.645 30.29%
2018 21.077.552 16.67%
2019 31.145.000 32.32%
2020 15.950.000 -95.27%
2021 19.762.000 19.29%
2022 11.399.000 -73.37%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Laboratorio Reig Jofre, S.A. Equity
Year Equity Growth
2004 37.140.515
2005 79.245.000 53.13%
2006 147.735.000 46.36%
2007 140.913.000 -4.84%
2008 131.948.000 -6.79%
2009 93.587.000 -40.99%
2010 73.354.000 -27.58%
2011 86.590.000 15.29%
2012 86.753.000 0.19%
2013 75.617.000 -14.73%
2014 118.171.704 36.01%
2015 126.174.485 6.34%
2016 133.292.526 5.34%
2017 141.559.244 5.84%
2018 149.739.662 5.46%
2019 178.138.000 15.94%
2020 184.478.000 3.44%
2021 188.514.000 2.14%
2022 194.553.000 3.1%
2023 202.362.000 3.86%
2023 204.254.000 0.93%
2024 209.539.000 2.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Laboratorio Reig Jofre, S.A. Assets
Year Assets Growth
2004 52.635.988
2005 156.395.000 66.34%
2006 288.975.000 45.88%
2007 317.553.000 9%
2008 307.497.000 -3.27%
2009 200.180.000 -53.61%
2010 183.088.000 -9.34%
2011 165.377.000 -10.71%
2012 98.059.000 -68.65%
2013 83.766.000 -17.06%
2014 180.743.769 53.65%
2015 187.053.622 3.37%
2016 205.632.616 9.04%
2017 203.337.106 -1.13%
2018 219.675.048 7.44%
2019 313.615.000 29.95%
2020 317.151.000 1.11%
2021 324.976.000 2.41%
2022 321.191.000 -1.18%
2023 338.881.000 5.22%
2023 332.444.000 -1.94%
2024 356.030.000 6.62%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Laboratorio Reig Jofre, S.A. Liabilities
Year Liabilities Growth
2004 15.495.473
2005 77.150.000 79.92%
2006 141.240.000 45.38%
2007 176.640.000 20.04%
2008 175.549.000 -0.62%
2009 106.593.000 -64.69%
2010 109.734.000 2.86%
2011 78.787.000 -39.28%
2012 11.306.000 -596.86%
2013 8.149.000 -38.74%
2014 62.572.065 86.98%
2015 60.879.137 -2.78%
2016 72.340.090 15.84%
2017 61.777.862 -17.1%
2018 69.935.386 11.66%
2019 135.477.000 48.38%
2020 132.673.000 -2.11%
2021 136.462.000 2.78%
2022 122.943.000 -11%
2023 136.609.000 10%
2023 124.619.000 -9.62%
2024 142.881.000 12.78%

Laboratorio Reig Jofre, S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
4.14
Net Income per Share
0.12
Price to Earning Ratio
24.19x
Price To Sales Ratio
0.68x
POCF Ratio
19.74
PFCF Ratio
19.74
Price to Book Ratio
1.07
EV to Sales
0.86
EV Over EBITDA
7.81
EV to Operating CashFlow
25.17
EV to FreeCashFlow
25.17
Earnings Yield
0.04
FreeCashFlow Yield
0.05
Market Cap
0,22 Bil.
Enterprise Value
0,29 Bil.
Graham Number
2.61
Graham NetNet
-0.55

Income Statement Metrics

Net Income per Share
0.12
Income Quality
5.17
ROE
0.05
Return On Assets
0.03
Return On Capital Employed
0.06
Net Income per EBT
0.86
EBT Per Ebit
0.78
Ebit per Revenue
0.04
Effective Tax Rate
0.1

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.34
Operating Profit Margin
0.04
Pretax Profit Margin
0.03
Net Profit Margin
0.03

Dividends

Dividend Yield
0.01
Dividend Yield %
1.16
Payout Ratio
0
Dividend Per Share
0.03

Operating Metrics

Operating Cashflow per Share
0.14
Free CashFlow per Share
0.14
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.05
Return on Tangible Assets
0.03
Days Sales Outstanding
82
Days Payables Outstanding
92.09
Days of Inventory on Hand
119.83
Receivables Turnover
4.45
Payables Turnover
3.96
Inventory Turnover
3.05
Capex per Share
0

Balance Sheet

Cash per Share
0,09
Book Value per Share
2,66
Tangible Book Value per Share
1.58
Shareholders Equity per Share
2.62
Interest Debt per Share
0.74
Debt to Equity
0.28
Debt to Assets
0.16
Net Debt to EBITDA
1.68
Current Ratio
1.48
Tangible Asset Value
0,13 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
232597000
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.24
Average Receivables
0,07 Bil.
Average Payables
0,06 Bil.
Average Inventory
68297000
Debt to Market Cap
0.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Laboratorio Reig Jofre, S.A. Dividends
Year Dividends Growth
2013 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 1 0%
2023 0 0%
2024 0 0%

Laboratorio Reig Jofre, S.A. Profile

About Laboratorio Reig Jofre, S.A.

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Despí, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.

CEO
Mr. Ignasi Biosca Reig
Employee
1.323
Address
Gran Capita, 10
Barcelona, 08970

Laboratorio Reig Jofre, S.A. Executives & BODs

Laboratorio Reig Jofre, S.A. Executives & BODs
# Name Age
1 Mr. Marc Ramos
Head of Tax & Financial Consolidation
70
2 Ms. Estefanía Ruiz
Group Chief Accountant & Controller
70
3 Ms. Victoria Serra
Manager of Human Resources
70
4 Mr. Adolf Rousaud Viñas
Non-Director Secretary
70
5 Ms. Roser Gomila Zabala
Chief Financial Officer
70
6 Mr. Ignasi Biosca Reig
Chief Executive Officer & Executive Director
70

Laboratorio Reig Jofre, S.A. Competitors

Almirall, S.A. Logo
Almirall, S.A.

ALM.MC

(2.5)
Pharma Mar, S.A. Logo
Pharma Mar, S.A.

PHM.MC

(1.2)
Faes Farma, S.A. Logo
Faes Farma, S.A.

FAE.MC

(4.0)